合生制剂改善前驱糖尿病患者的血糖及胰岛素敏感性
创作:szx 审核:szx 2018年06月30日
  • 纳入120名成年前驱糖尿病患者,进行一项为期24周的随机双盲安慰剂对照临床试验,患者分别摄入益生菌、合生制剂、安慰剂;
  • 益生菌为冻干的乳杆菌属及双歧杆菌属菌株,合生制剂为益生菌+菊粉;
  • 与安慰剂组相比,合生制剂显著降低了空腹血糖、胰岛素抵抗性,并显著提升了胰岛素敏感性;
  • 另外,补充合生制剂及益生菌可显著降低HbA1C,3组间的β细胞功能无显著差异。
主编推荐语
szx
在Acta Diabetologica上发表的一项最新随机双盲对照临床试验的结果中,合生制剂(包含乳杆菌属及双歧杆菌属菌株+菊粉)可显著降低前驱糖尿病成年患者的空腹血糖,并提升胰岛素敏感性,减少胰岛素抵抗。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Acta Diabetologica [IF:3.418]

The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial

补充益生菌与合生制剂对前驱糖尿病成年患者的葡萄糖及胰岛素代谢的影响:一项随机双盲对照临床试验

10.1007/s00592-018-1175-2

2018-06-22, Article

Abstract & Authors:展开

Abstract:收起
AIMS: Probiotics and/or prebiotics could be a promising approach to improve metabolic disorders by favorably modifying the gut microbial composition.
OBJECTIVES: To assess the effects of probiotics and synbiotic on glycemic indices in prediabetic individuals who are at risk of type 2 diabetes and its complications.
METHODS: In a double-blind, randomized, placebo-controlled parallel-group clinical trial, 120 prediabetic adults participated and were randomly allocated to receive either probiotics or synbiotic or placebo supplements for 24 weeks. Anthropometric measurements, food record, physical activity and glycemic biomarkers including glycated hemoglobin (HbA1C), fasting plasma glucose (FPG), fasting insulin levels (FIL), homoeostasis model assessment for insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), and β-cell function (HOMA-B) were assessed at baseline and repeated at 12 and 24 weeks and compared within and between three groups using repeated measure ANOVA.
RESULTS: Compared with the placebo, synbiotic supplementation resulted in a higher significant reduction in FPG (- 6.5 ± 1.6 vs. - 0.82 ± 1.7 mg/dL, P = 0.01), FIL (- 2.6 ± 0.9 vs. - 0.8 ± 0.8 µIU/mL, P = 0.028), and HOMA-IR (- 0.86 ± 0.3 vs. - 0.16 ± 0.25, P = 0.007), and a significant elevation in the QUICKI (+ 0.01 ± 0.003 vs. + 0.003 ± 0.002, P = 0.006). In addition, significant decreases in HbA1C was seen following the supplementation of probiotics and synbiotic compared with the placebo (- 0.12 ± 0.06 and - 0.14 ± 0.05 vs. +0.07 ± 0.06%, P = 0.005 and 0.008, respectively). HOMA-B was not found to be different between or within the three groups.
CONCLUSION: Glycemic improvement by probiotics and particularly synbiotic supplements in prediabetic individuals has been supported by current study. However, further studies are required for optimal recommendations in this important area of patient treatment.
TRIAL REGISTRATION: Iranian Registry of Clinical Trials: IRCT201511032321N2, Date registered February 27, 2016.

First Authors:
Nazila Kassaian

Correspondence Authors:
Masoud Amini

All Authors:
Nazila Kassaian,Awat Feizi,Ashraf Aminorroaya,Parvaneh Jafari,Maryam Tajabadi Ebrahimi,Masoud Amini

评论